GFH-925

The global KRAS inhibitors market has experienced over 400% growth since the first approval in 2021, with four drugs now authorized for treating cancers with KRAS mutations.

The combination of fulzerasib and cetuximab demonstrated an 80% objective response rate with 100% disease control rate in previously untreated patients with KRAS G12C-mutated non-small cell lung cancer, according to updated KROCUS trial data.

The FDA has approved Lumakras (sotorasib) combined with Vectibix (panitumumab) for treating KRAS G12C-mutated metastatic colorectal cancer in adults after prior chemotherapy.

China's NMPA has approved Innovent's taletrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

The KRAS inhibitors market is projected to grow significantly, driven by increasing cancer incidence and advancements in targeted therapies.